At what enterprise value was NUTRAQ acquired in 2021?

During the acquisition of NUTRAQ by ORKLA in 2021, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b NOK. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of NUTRAQ when it was acquired by ORKLA?

The estimated EV/EBITDA multiple for NUTRAQ is in the range of 15x - 25x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was NUTRAQ acquired by ORKLA?

NUTRAQ was acquired by ORKLA in 2021.

What was the revenue of NUTRAQ at the time of the deal?

The revenue of NUTRAQ at the time of the deal is estimated to be in the range of 450M - 900M NOK. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of NUTRAQ during the acquisition?

NUTRAQ's EBITDA is estimated to be in the range of 100M - 200M NOK. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the NUTRAQ acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the NUTRAQ deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.orkla.com/media/press-releases/2021/orklas-acquisition-of-nutraq-completed/

← DATABASE

Home Database Healthcare & PharmaNUTRAQ

07/2021

NUTRAQ acquired by ORKLA

NORWAY Life Sciences / Nutrition & Dietary Supplements EV 3b - 100b NOK

Context

Orkla completed its acquisition of NutraQ to strategically enhance its presence in high-growth market segments, specifically the health category and the direct-to-consumer (D2C) channel. The transaction provides Orkla with a new, subscription-based business model, diversifying its traditional go-to-market strategies and offering exciting growth opportunities. Orkla's leadership expressed admiration for the target's successful use of subscription solutions to build a significant customer base with direct home delivery. The strategic plan involves continuing the development of NutraQ's established concepts while simultaneously exploring new possibilities for applying the D2C model across Orkla's broader portfolio. To preserve the target's unique competencies and entrepreneurial culture, NutraQ will continue to operate as a stand-alone entity within the Orkla Care business area, with its existing executive management team remaining in place. The deal represents a logical next step for NutraQ, transitioning it from private equity ownership under Impilo and Sana Pharma Holding to a long-term industrial owner poised to support its next phase of growth and expansion. The transaction received all necessary approvals from relevant competition authorities prior to its completion.

NUTRAQ, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

NutraQ is a prominent supplier specializing in subscription-based health and wellness products, primarily serving the Nordic market. Established in Norway in 2002, the company has since expanded its operational footprint to include Denmark, Finland, Sweden, the Czech Republic, Slovakia, the Netherlands, and Poland. Despite this expansion, the four Nordic countries consistently constitute the vast majority of its turnover. The company's core business model is centered on a direct-to-consumer (D2C) approach, leveraging subscription services to deliver a range of health and wellness concepts directly to customers' homes. This model has proven successful, supporting significant organic growth in its customer base; in the period 2018-2020, the number of active subscriptions grew by an average of 13 percent per year. Headquartered in Oslo, Norway, NutraQ operates with a dedicated team of approximately 170 employees. The company's strategy focuses on building and maintaining strong customer relationships through its recurring revenue model and continuously developing attractive product offerings within the health and wellness space. Its well-established platform is designed to support further growth and geographic expansion.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (NOK)

Year

Rev

EBITDA

EBIT

2020

2019

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
11/2021	COLOPLAST	ATOS MEDICAL	SWEDEN	Life Sciences	Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market
09/2021	PERRIGO COMPANY	HRA PHARMA	FRANCE	Life Sciences	The acquisition of HRA Pharma by Perrigo signifies the "crowning achievement" of the acquirer’s structural transformation into a pure-play consumer self-care leader. The strategic rationale for this transaction centers on a "portfolio-premium" maneuver, merging the target’s high-growth, margin-accretive branded assets with the acquirer’s massive expert direct go-to-market platform
07/2021	MONTAGU PRIVATE EQUITY	INTECH MEDICAL	FRANCE	Life Sciences	Intech Medical, a global leader in the manufacturing of orthopedic surgical instruments and implants, has entered into an agreement to be acquired by Montagu Private Equity. The transaction marks the exit of Eurazeo (specifically its mid-cap subsidiary) and Andera Partners, who have held a majority stake in the French group since 2017
07/2021	PARTNERS GROUP	PHARMATHEN	GREECE	Life Sciences	Partners Group acquired 100% of Pharmathen from BC Partners, which had acquired the company in 2015. During its ownership, BC Partners invested over €250 million in R&D and new FDA-approved production facilities, nearly doubled the employee headcount, and repositioned Pharmathen from a traditional European generics manufacturer into a technology-driven global leader in complex drug delivery
04/2021	DIASORIN	LUMINEX CORPORATION	UNITED STATES	Life Sciences	DiaSorin has finalized the acquisition of Luminex Corporation, an operation designed to fundamentally strengthen the group’s competitive positioning within the molecular diagnostics and life sciences sectors
04/2021	NAXICAP PARTNERS	LAGARRIGUE	FRANCE	Life Sciences	Naxicap Partners acquired a majority stake (~80%) in Groupe Lagarrigue from Ardian and iXO Private Equity. The management team reinvested to hold the remaining ~20%. Naxicap prevailed in a competitive auction process managed by Edmond de Rothschild Corporate Finance, beating out offers from IK Investment Partners and Cobepa
03/2021	CVC	COOPER-VEMEDIA	FRANCE	Life Sciences	CVC acquired a majority stake in Cooper-Vemedia from Charterhouse. The transaction, valued at EUR2.2 billion, was won in a competitive process against a PAI/Ontario Teachers' consortium. The acquisition reflects CVC's appetite for high-cash-flow businesses with low capital intensity (Capex ~EUR10M)
02/2021	SIPAREX	WINNCARE	FRANCE	Life Sciences	Siparex ETI has entered into exclusive negotiations to acquire a majority stake in Winncare, marking the first investment of its Siparex ETI 5 fund. This transaction follows a successful period of ownership by IDI, which originally took control of the group in 2014 and supported a doubling of the company,s size through international expansion
01/2021	MONTAGU PRIVATE EQUITY	IMV TECHNOLOGIES	FRANCE	Life Sciences	Montagu Private Equity entered into exclusive negotiations to acquire a majority stake in IMV Technologies from Qualium Investissement. Montagu prevailed in a competitive process against CVC Capital Partners
01/2021	ARDIAN / BNP PARIBAS DEVELOPPEMENT	PROTEOR	FRANCE	Life Sciences	For the first time since its founding in 1913, Proteor has opened its capital to institutional investors through a primary Owner Buy-Out (OBO). Ardian Growth and BNP Paribas Développement have injected €24 million (a mix of convertible bonds and equity) to support the group's next phase of expansion

REFERENCES

Valuation range: EV 3b - 100b NOK

Revenue range: 450M - 900M NOK

EBITDA range: 100M - 200M NOK

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of NUTRAQ by ORKLA are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: nutraq

Acquirer: orkla